EP Patent

EP3938363A1 — Solid state forms of ripretinib

Assigned to Deciphera Pharmaceuticals LLC · Expires 2022-01-19 · 4y expired

What this patent protects

The present disclosure relates to solid state forms of ripretinib, processes for preparation thereof, as well as a pharmaceutical composition including the same.

USPTO Abstract

The present disclosure relates to solid state forms of ripretinib, processes for preparation thereof, as well as a pharmaceutical composition including the same.

Drugs covered by this patent

Patent Metadata

Patent number: EP3938363A1
Jurisdiction: EP
Classification: —
Expires: 2022-01-19
Drug substance claim: No
Drug product claim: No
Assignee: Deciphera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.